Prevencio Granted US Patent for Highly Accurate, Artificial Intelligence-driven Blood Test for Obstructive Coronary Artery Disease

Prevencio has announced that the United States Patent and Trademark Office has issued a patent for its highly accurate blood test, HART CADhs, which assesses a patient’s risk of obstructive coronary artery disease, also referred to as obstructive heart disease. The company utilized its Artificial Intelligence-driven HART platform and expertise in cardiac blood tests to develop HART CADhs.